Company Overview and News
Apr 25, 2018 (LBO) – Sri Lanka’s Nations Trust Bank has launched a API Banking Platform enabling clients to integrate the bank’s services directly into their own systems and workflows.
From left: Finlays Colombo Limited Director Naresh Ratwatte, Finlays Colombo Limited Chairman and Managing Director Hunter Crawford, John Keells Holdings PLC Property Group President Suresh Rajendra and John Keells Holdings PLC Property Group Sector Head Nayana Mawilmada at the signing of the joint venture agreement
RIL Chairman Sunil Wijesinha ringing the bell, flanked by RIL CEO/Executive Director Hiroshini Fernando (left), CSE Chairman Vajira Kulatilaka (right) and other RIL and CSE officials Pic by Pradeep Pathirana
May 02, 2017 (LBO) – Sri Lanka’s blue chip John Keells Holdings plans to boost local creative and intellectual talent with the launch of its second John Keells X “Open Innovation Challenge 2017”
Dec 28, 2016 (Reuters) – Sri Lankan shares closed about half a percent higher on Wednesday, recovering from a more than eight-month closing low hit in the previous session, led by blue chips such as John Keells Holdings and Hatton National Bank.
Dec 23, 2016 (Reuters) – Sri Lankan shares edged up on Friday, snapping eight straight sessions of falls and moving away from a more than eight-month closing low hit in the previous session, while turnover was low in holiday-thinned trade as investors stayed away from markets ahead of the Christmas weekend.
Reuters – Sri Lankan shares ended weaker for a second straight session on Tuesday, led by top conglomerate John Keells Holdings, though foreign investors’ buying and gains in financials helped to cap the fall.
Dr. Hans Wijesuriya, who is the Chief Executive Officer and Director of Dialog Axiata PLC has been appointed to the Board of Directors of John Keells Holdings PLC.
Sri Lanka’s most iconic mixed development project, Cinnamon Life, announced the launch of ‘The Suites at Cinnamon Life’, the second residential tower to be constructed as part of a 4.5 million square foot integrated resort by Waterfront Properties (Private) Limited, a member of the John Keells Group.
(PRESS RELEASE) – Sri Lanka’s most iconic mixed development project, Cinnamon Life, announced the launch of ‘The Suites at Cinnamon Life’, the second residential tower to be constructed as part of a 4.5 million square foot integrated resort by Waterfront Properties (Private) Limited, a member of the John Keells Group.
Colombo Fort was lit up in brilliant shades last Thursday night as Fairway Holdings celebrated the grand opening of its brand new city hotel – the ZMAX Fairway Colombo. The 15th of September 2016 marked the completion of yet another milestone in the real estate giant’s journey as it made its first entry into the hospitality industry of Sri Lanka.
Sept 21, 2016 (LBO) – Adverse weather conditions, combined with rising costs and greater competition, threaten to weaken Sri Lanka’s position in the global tea industry, though efforts to develop new markets could help offset downturns in exports and revenue, the Oxford Business Group said in a note on the economy.
Reuters – Aug 18 Sri Lankan shares posted a three-month closing high on Thursday, led by gains in blue chips such as John Keells Holdings Plc and Ceylon Tobacco Company Plc, while foreign investor buying also boosted sentiment.
John Keells Office Automation (Pvt) Ltd (JKOA) hosted its technical service provider network to a day of discussion, performance evaluation and celebration at the Hilton. Following the main programme, high performing technicians were recognised for their exceptional performance over the last year.
Reuters – Sri Lankan shares ended slightly lower on Wednesday as investors sold blue-chips such as John Keells Holdings Plc and Ceylon Tobacco Company Plc even as the market awaited directions on the country’s economic policy.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...